# OnCo record lung-uk-drug-access (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lung-uk-drug-access/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lung-uk-drug-access" ;
  schema:name "Lung cancer drugs in England: what NICE has recommended"@en ;
  schema:alternateName "NICE lung cancer guidance"@en, "Lung cancer drug funding England"@en ;
  schema:description "Which lung cancer drugs the NHS in England funds, and which it does not. Every reference number below was opened on the NICE website in September 2026 and its recommendation read."@en ;
  schema:url <https://onco.cc/terms/lung-uk-drug-access/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://www.nice.org.uk/guidance/ng122>, <https://www.nice.org.uk/guidance/ta1043>, <https://www.nice.org.uk/guidance/ta1127>, <https://www.nice.org.uk/guidance/ta1103>, <https://www.nice.org.uk/guidance/ta1099> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/nintedanib/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/lurbinectedin/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/> .